Ryvu Therapeutics SA
Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, RVU120, is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It… Read more
Ryvu Therapeutics SA (RVU) - Net Assets
Latest net assets as of September 2025: zł71.22 Million PLN
Based on the latest financial reports, Ryvu Therapeutics SA (RVU) has net assets worth zł71.22 Million PLN as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł255.34 Million) and total liabilities (zł184.12 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł71.22 Million |
| % of Total Assets | 27.89% |
| Annual Growth Rate | 38.52% |
| 5-Year Change | -35.69% |
| 10-Year Change | 206.92% |
| Growth Volatility | 199.87 |
Ryvu Therapeutics SA - Net Assets Trend (2010–2024)
This chart illustrates how Ryvu Therapeutics SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ryvu Therapeutics SA (2010–2024)
The table below shows the annual net assets of Ryvu Therapeutics SA from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | zł143.88 Million | -44.57% |
| 2023-12-31 | zł259.59 Million | -24.40% |
| 2022-12-31 | zł343.39 Million | +102.68% |
| 2021-12-31 | zł169.42 Million | -24.27% |
| 2020-12-31 | zł223.72 Million | +86.81% |
| 2019-12-31 | zł119.76 Million | -38.54% |
| 2018-12-31 | zł194.86 Million | +204.49% |
| 2017-12-31 | zł64.00 Million | +14.87% |
| 2016-12-31 | zł55.71 Million | +18.84% |
| 2015-12-31 | zł46.88 Million | +406.61% |
| 2014-12-31 | zł9.25 Million | +195.78% |
| 2013-12-31 | zł3.13 Million | -43.45% |
| 2012-12-31 | zł5.53 Million | -51.73% |
| 2011-12-31 | zł11.46 Million | +662.89% |
| 2010-12-31 | zł1.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ryvu Therapeutics SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10872994994.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | zł9.25 Million | 6.43% |
| Other Comprehensive Income | zł-273.67 Million | -190.20% |
| Other Components | zł519.75 Million | 361.23% |
| Total Equity | zł143.88 Million | 100.00% |
Ryvu Therapeutics SA Competitors by Market Cap
The table below lists competitors of Ryvu Therapeutics SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kyeryong Const
KO:013580
|
$100.56 Million |
|
Dinhvu Port Investment Development JSC
VN:DVP
|
$100.63 Million |
|
HKScan Oyj Series A
LSE:0ISM
|
$100.63 Million |
|
First Real Estate Investment Trust of New Jersey Inc
PINK:FREVS
|
$100.68 Million |
|
Itafos Inc
PINK:MBCF
|
$100.54 Million |
|
Golden Ventures Leasehold Real Estate Investment Trust
BK:GVREIT
|
$100.53 Million |
|
KNIGHTS GROUP HOL LS-002
F:77Q
|
$100.53 Million |
|
Kudelski
SW:KUD
|
$100.52 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ryvu Therapeutics SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 259,592,000 to 143,884,000, a change of -115,708,000 (-44.6%).
- Net loss of 111,435,000 reduced equity.
- Other comprehensive income decreased equity by 4,274,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł-111.44 Million | -77.45% |
| Other Comprehensive Income | zł-4.27 Million | -2.97% |
| Other Changes | zł1.00K | +0.0% |
| Total Change | zł- | -44.57% |
Book Value vs Market Value Analysis
This analysis compares Ryvu Therapeutics SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.74x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 162.27x to 3.74x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | zł0.14 | zł23.30 | x |
| 2011-12-31 | zł1.10 | zł23.30 | x |
| 2012-12-31 | zł0.53 | zł23.30 | x |
| 2013-12-31 | zł0.30 | zł23.30 | x |
| 2014-12-31 | zł0.88 | zł23.30 | x |
| 2015-12-31 | zł3.56 | zł23.30 | x |
| 2016-12-31 | zł4.03 | zł23.30 | x |
| 2017-12-31 | zł4.52 | zł23.30 | x |
| 2018-12-31 | zł12.36 | zł23.30 | x |
| 2019-12-31 | zł7.50 | zł23.30 | x |
| 2020-12-31 | zł13.34 | zł23.30 | x |
| 2021-12-31 | zł8.79 | zł23.30 | x |
| 2022-12-31 | zł18.73 | zł23.30 | x |
| 2023-12-31 | zł11.34 | zł23.30 | x |
| 2024-12-31 | zł6.22 | zł23.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ryvu Therapeutics SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -77.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -142.92%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 2.63x
- Recent ROE (-77.45%) is below the historical average (-33.42%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -131.36% | -22.31% | 0.86x | 6.84x | zł-2.12 Million |
| 2011 | -38.73% | -49.22% | 0.52x | 1.53x | zł-5.58 Million |
| 2012 | -116.19% | -68.24% | 0.61x | 2.77x | zł-6.98 Million |
| 2013 | -76.24% | -18.14% | 0.73x | 5.75x | zł-2.70 Million |
| 2014 | 63.22% | 20.27% | 1.08x | 2.90x | zł4.92 Million |
| 2015 | 13.50% | 15.28% | 0.63x | 1.40x | zł1.62 Million |
| 2016 | 4.91% | 5.65% | 0.54x | 1.61x | zł-2.82 Million |
| 2017 | 10.28% | 7.30% | 0.85x | 1.66x | zł177.14K |
| 2018 | -0.06% | -0.14% | 0.30x | 1.33x | zł-19.30 Million |
| 2019 | -30.06% | -84.57% | 0.23x | 1.53x | zł-47.97 Million |
| 2020 | -14.16% | -205.57% | 0.05x | 1.32x | zł-54.06 Million |
| 2021 | -49.02% | -706.91% | 0.05x | 1.42x | zł-95.21 Million |
| 2022 | -24.40% | -215.91% | 0.08x | 1.38x | zł-118.12 Million |
| 2023 | -35.48% | -196.57% | 0.12x | 1.55x | zł-118.07 Million |
| 2024 | -77.45% | -142.92% | 0.21x | 2.63x | zł-125.82 Million |
Industry Comparison
This section compares Ryvu Therapeutics SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $95,048,057
- Average return on equity (ROE) among peers: -39.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ryvu Therapeutics SA (RVU) | zł71.22 Million | -131.36% | 2.59x | $100.54 Million |
| Bioceltix S.A. (BCX) | $1.91 Million | -83.78% | 0.69x | $71.31 Million |
| Bioton S.A. (BIO) | $619.64 Million | 5.47% | 0.40x | $42.39 Million |
| Captor Therapeutics S.A. (CTX) | $124.20 Million | -26.23% | 0.16x | $69.93 Million |
| Mabion S.A. (MAB) | $-54.16 Million | 0.00% | 0.00x | $31.56 Million |
| Molecure S.A. (MOC) | $126.45 Million | -10.71% | 0.09x | $21.11 Million |
| Nanogroup SA (NNG) | $8.37 Million | -119.60% | 1.43x | $12.30 Million |
| Pharmena S.A. (PHR) | $8.98 Million | -45.66% | 0.29x | $2.62 Million |
| PolTREG S.A. (PTG) | $12.83 Million | -6.84% | 0.27x | $16.72 Million |
| Pure Biologics Spólka Akcyjna (PUR) | $7.21 Million | -65.22% | 2.02x | $2.90 Million |